Alexandria Real Estate Equities Aktie News

Alexandria Real Estate generated an 11% return in Q3. It may be starting to turn around its performance. With a 6.3% yield, a 57% payout ratio, and solid AFFO, ARE's dividend security stands out among healthcare REITs despite sector headwinds. I analyzed a catalyst that investors sometimes forget about in ARE: the potential of Big Pharma and Big Biotech.

U.S. equity markets rallied to fresh record-highs this past week as investors leaned into rate cut expectations following a wave of soft employment data and a Federal Government shutdown. For the fourth time since 1995, the federal government entered a partial "shutdown" after the U.S. Senate failed to reach the 60-vote threshold required for passage of appropriations. Defering to experience fr...

After a career that spanned two decades of experience at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.

ARE demonstrates resilience in a challenging life science real estate market, leveraging its mega-campus model and strong tenant relationships. Despite industry headwinds and high vacancy rates, ARE maintains robust leasing activity, positive spreads, and expects year-end occupancy between 91% and 92.5%. Long-term tailwinds, including projected growth in global pharmaceutical sales and AI-drive...

Alexandria Real Estate Equities is rated a 'Buy' for its undervalued price, high 6.3% yield, and strong long-term prospects. ARE's mega-campus strategy, robust tenant base, and critical role in life sciences support resilient cash flows and future growth. Despite recent occupancy pressures, ARE shows signs of recovery with improving leasing activity, a healthy development pipeline, and solid fi...

PASADENA, Calif. , Sept. 26, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced the opening of Lilly Gateway Labs San Diego, powered by Alexandria, on the One Alexandria Square Megacamp...

Recent economic data has weakened market optimism. Gold has hit record highs, Treasury yields have fallen, and the dollar index continues to deteriorate as investors seek safety. Despite negative economic signals, growth-driven stocks have reached new highs, defying broader market caution.

Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as undervalued winners and recommended as buys for income-focused investors.